{
    "clinical_study": {
        "@rank": "21866", 
        "acronym": "Celecoxib", 
        "arm_group": {
            "arm_group_label": "Celecoxib", 
            "arm_group_type": "Experimental", 
            "description": "1-4 mg intravitreal injection ofCelecoxib"
        }, 
        "brief_summary": {
            "textblock": "Intraocular delivery of celecoxib will be an effective means to treat inflammation and\n      macular edema and prevent structural complications and vision loss in patients with chronic\n      inflammation or macular edema who are unable to tolerate corticosteroids due to their side\n      effects."
        }, 
        "brief_title": "Intraviteral Celecoxib for Chronic Uveitis", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Inflammation", 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Uveitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Specific Aims I: Test the safety of intraocular injection of 1mg and 4mg celecoxib in\n      patients who have chronic inflammation or macular edema who are unable to tolerate\n      corticosteroids due to their side effects.\n\n      II: Test the efficacy of intraocular 1mg and 4mg celecoxib in treating inflammation or\n      structural complications of inflammation (macular edema) in patients who are unable to\n      tolerate corticosteroids due to their side effects.\n\n      After investigational new drug application and Vanderbilt IRB approval, celecoxib will be\n      compounded by the Investigational Drug Service of the Vanderbilt Medical Center and packaged\n      in individual sterile single use syringes for intraocular injection within 2 hours of\n      preparation. Pharmaceutical grade celecoxib will be obtained from the drug manufacturer\n      (Pfizer) with certificate analysis and compounded in sterile dimethyl sulfoxide following\n      strict sterile technique."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic inflammation and/or macular edema despite maximal medical treatment Unable to\n             tolerate corticosteroids due to side effects Aphakic or Psuedophakic subjects\n\n        Exclusion Criteria:\n\n          -  15 years or younger Have active ocular infection Pregnancy Phakic subjects"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131012", 
            "org_study_id": "IND for Celecoxib"
        }, 
        "intervention": {
            "arm_group_label": "Celecoxib", 
            "description": "1-4 mg intravitreal celecoxib", 
            "intervention_name": "Intravitreal Celecoxib", 
            "intervention_type": "Drug", 
            "other_name": [
                "Celebrex", 
                "NSAIDS"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Macular edema", 
        "lastchanged_date": "May 1, 2014", 
        "number_of_arms": "1", 
        "official_title": "Intravitreal Celecoxib for Chronic Uveitis: A Phase I Investigational Safety Study", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Participant will receive an intravitreal injection of the Celecoxib and be followed for any possible adverse events", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131012"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vanderbilt University", 
            "investigator_full_name": "Stephen J. Kim, MD", 
            "investigator_title": "Assistant Professor of Ophthalmology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Participant will receive the intravitreal injection of celecoxib day 1 and be followed for efficacy. The efficacy will be determined from the ophthalmic exams and aqueous samples", 
            "measure": "Efficacy", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "source": "Vanderbilt University", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Vanderbilt University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}